Search
Search
Close this search box.

Wellness brand Prima rakes in $9.2m in big funding round

An American wellness brand has raked in $9.2m in a bumper seed funding round.

The Uplifters’ Prima – commonly known as Prima – will use the cash to fund retail expansions and clinical research.

Founded in 2019, the CBD firm produces more than a dozen consumer products pitched at the beauty and self-care market.

The funding round was led by a host of venture capital firms, primarily Greycroft, H Venture, Defy and Lerer Hippeau.

Among the backers is Emerald Health Therapeutics, a Canadian cannabinoid product producers which will give Prima ‘access to proprietary…innovations’

Christopher Gavigan, Prima founder and CEO: “As an experienced team building a CPG platform of the highest integrity, credibility, consciousness and quality, we realise it is our duty and responsibility to impose uncompromising and rigorous standards and boldly self-regulate to lead this emerging functional wellness industry forward.

“With this meaningful funding, Prima will continue its focused investments in plant-driven, clean formulation science, R&D ownership, efficacy validation, operational infrastructure, sustainability initiatives and tech-enabled consumer experiences.

“Prima is even more emboldened to broaden our digital and retail strategies, build best-in-class education partnerships and ensure these therapeutic botanical compounds are destigmatised, understood and accessible for all.”

According to a statement, the company expects to have its products stocked in 800 new outlets this year alone.

Laurel Angelica Myers, Prima COO, said: “Our team brings institutional strategy, sophistication, capability and execution to a burgeoning sector that has yet to see any brands like Prima.

“As a Certified B Corporation that is Carbon and Plastic Neutral Certified and EWG Verified, Prima is built on strong, sophisticated, sustainable infrastructure across every touchpoint of the business.”

[activecampaign form=31]

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?